# Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma

> **NCT06907602** · PHASE2,PHASE3 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Locally Advanced Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Chemotherapy
- **DRUG:** Immunotherapy (Pembrolizumab)
- **RADIATION:** radiotherapy

## Key facts

- **NCT ID:** NCT06907602
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-12
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-04-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06907602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06907602, "Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06907602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*